Gavin Fredrickson
Overview
Explore the profile of Gavin Fredrickson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
233
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fredrickson G, Florczak K, Barrow F, Mahmud S, Dietsche K, Wang H, et al.
Hepatology
. 2024 Sep;
PMID: 39292863
Background And Aims: For patients with obesity and metabolic syndrome, bariatric procedures such as vertical sleeve gastrectomy (VSG) have a clear benefit in ameliorating metabolic dysfunction-associated steatohepatitis (MASH). While the...
2.
Patterson M, Firulyova M, Xu Y, Hillman H, Bishop C, Zhu A, et al.
Nat Cardiovasc Res
. 2024 Apr;
2(11):1015-1031.
PMID: 38646596
Atherosclerosis is driven by the expansion of cholesterol-loaded 'foamy' macrophages in the arterial intima. Factors regulating foamy macrophage differentiation and survival in plaque remain poorly understood. Here we show, using...
3.
Barrow F, Wang H, Fredrickson G, Florczak K, Ciske E, Khanal S, et al.
bioRxiv
. 2023 Nov;
PMID: 38014163
B cells play a crucial role in the pathogenesis of metabolic dysfunction-associated steatohepatitis (MASH), a severe form of steatotic liver disease that if persistent can lead to cirrhosis, liver failure,...
4.
Barrow F, Fredrickson G, Wang H, Revelo X
STAR Protoc
. 2023 Nov;
4(4):102743.
PMID: 37995192
Hepatic inflammation, driven by immune cells such as B and T lymphocytes, is a hallmark feature of metabolic dysfunction-associated steatohepatitis (MASH). Here, we detail a robust cytometry by time-of-flight (CyTOF)...
5.
Revelo X, Fredrickson G, Florczak K, Barrow F, Dietsche K, Wang H, et al.
Res Sq
. 2023 Nov;
PMID: 37961666
For patients with obesity and metabolic syndrome, bariatric procedures such as vertical sleeve gastrectomy (VSG) have a clear benefit in ameliorating metabolic dysfunction-associated steatohepatitis (MASH). While the effects of bariatric...
6.
Wang H, Barrow F, Fredrickson G, Florczak K, Nguyen H, Parthiban P, et al.
bioRxiv
. 2023 Oct;
PMID: 37873316
Nonalcoholic steatohepatitis (NASH), characterized by hepatic inflammation and cellular damage, is the most severe form of nonalcoholic fatty liver disease and the fastest-growing indication for a liver transplant. The intestinal...
7.
Liao C, Barrow F, Venkatesan N, Nakao Y, Mauer A, Fredrickson G, et al.
Front Immunol
. 2023 May;
14:1130184.
PMID: 37153573
Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid associated with nonalcoholic steatohepatitis (NASH). Immune cell-driven inflammation is a key determinant of NASH progression. Macrophages, monocytes, NK cells, T cells, NKT cells,...
8.
Revelo X, Parthiban P, Chen C, Barrow F, Fredrickson G, Wang H, et al.
Circ Res
. 2021 Oct;
129(12):1086-1101.
PMID: 34645281
Rationale: The initial hypertrophy response to cardiac pressure overload is considered compensatory, but with sustained stress, it eventually leads to heart failure. Recently, a role for recruited macrophages in determining...
9.
Hepatic lysosomal acid lipase overexpression worsens hepatic inflammation in mice fed a Western diet
Lopresti M, Cui W, Abernathy B, Fredrickson G, Barrow F, Desai A, et al.
J Lipid Res
. 2021 Oct;
62:100133.
PMID: 34624333
Nonalcoholic fatty liver disease (NAFLD) is characterized by the accumulation of lipid droplets in hepatocytes. NAFLD development and progression is associated with an increase in hepatic cholesterol levels and decreased...
10.
Fredrickson G, Barrow F, Dietsche K, Parthiban P, Khan S, Robert S, et al.
Mol Metab
. 2021 Jun;
53:101270.
PMID: 34118476
Objective: Non-alcoholic fatty liver disease (NAFLD) covers a wide spectrum of liver pathology ranging from simple fatty liver to non-alcoholic steatohepatitis (NASH). Notably, immune cell-driven inflammation is a key mechanism...